UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESM

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0104

Expires: December 31,

Estimated average burden

hours per response 0.5

1. Name and Address of Reporting Person*	Requiring Statement (Month/Day/Year) 4. to	Issuer Name and Ticker or Trading Symbol SYNTA PHARMACEUTICALS CORP [SNTA]			
Chen Lan Bo		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date of Original Filed (Month/Day/Year)		
(Last) (First) (Middle) 184 EAST EMERSON ROAD		(Che	(Check all applicable) X Director X 10% Owner Officer (give title below) (specify	6. Individual or Joint/Group Filin (Check Applicable Line) X Form filed by One Reporting Person	
(Street) LEXINGTON MA 02420		below)	Form filed by More than One Reporting Person		
(City) (State) (Zip)					

Table I - Non-Derivative Securities Beneficially Owned							
1. Title of Security (Instr. 4)	2. Amount of Securities Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Common Stock	742,024 (1)	D					
Common Stock	55,071 ⁽¹⁾	I	By Lan Bo Chen 2004 GRAT (2) (3)				
Common Stock	2,513,674 (1)	I	By trust (4) (3)				
Common Stock	142,223 (1)	I	By LAJ Holdings LLC (5) (3)				

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4)	Exercisable and		Securities Underlying Derivative Security (Instr.		Conversion or	l .	6. Nature of Indirect Beneficial Ownership		
	Date Exercisable	Expiration Date	Title	Amount or Number of SharesM		or Indirect (I) (Instr. 5)	(Instr. 5)		

Explanation of Responses:

- 1. Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which the number of shares of Common Stock was divided by 4.
- 2. These shares are owned directly by the Lan Bo Chen 2004 GRAT and indirectly by the Reporting Person as the granter.
- 3. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- 4. Of these shares, 2,004,016 are owned directly by the Wisteria Trust and indirectly by the Reporting Person as the husband of the trustee and beneficiary; 243,481 are owned directly by the Ann Chen Trust and indirectly by the Reporting Person as the husband of a trustee and the father of the beneficiary; 243,481 are owned directly by the Jane Chen Trust and indirectly by the Reporting Person as the husband of a trustee and the father of the beneficiary; 12,946 are owned directly by the Chen Grandchildren's Trust and indirectly by the Reporting Person as the husband of a trustee and the grandfather of the beneficiaries; 6,950 are owned directly by the Alexander Chen Wu 2002 Irrevocable Trust and indirectly by the Reporting Person as the husband of a trustee and the grandfather of the beneficiary; and 2,800 are owned directly by the Allison Chen Wu 2004 Irrevocable Trust and indrectly by the Reporting Person as the husband of a trustee and the grandfather of the beneficiary.
- 5. These shares are owned directly by LAJ Holdings LLC and indirectly by the Reporting Person as a co-manager of LAJ Holdings LLC.

/s/ Ann Margaret Eames.
Attorney-in-Fact

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Safi R. Bahcall, Ph.D., the President and Chief Executive Officer of Synta Pharmaceuticals Corp. (the "Company"), Keith S. Ehrlich, the Vice President, Finance and Administration, Chief Financial Officer of the Company, and Wendy E. Rieder, the Vice President, Intellectual Property and Legal Affairs, General Counsel of the Company, and Brian Keane, Daniel T. Kajunski, and Ann Margaret Eames of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, forms and authentication documents for EDGAR Filing Access;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents;
- (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not

assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-infact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 29th day of January 2007.

/s/ Lan Bo Chen Signature

Lan Bo Chen Print Name